Seppälä N H, Leinonen E V, Lehtonen M L, Kivistö K T
Department of Clinical Psychiatry, Tampere University Hospital, Finland.
Pharmacol Toxicol. 1999 Nov;85(5):244-6. doi: 10.1111/j.1600-0773.1999.tb02016.x.
Serum concentrations of clozapine and its main metabolite demethylclozapine were measured in 44 schizophrenic inpatients, of whom ten were non-smokers and 34 smokers. When comparing their clozapine dose and body weight-related serum drug levels, we found that clozapine and demethylclozapine concentrations were about 40% lower in the smoking than in the non-smoking group, probably due to an inducing effect of smoking on the cytochrome P450 (CYP) 1A2, which is involved in the metabolism of clozapine. We conclude that dosage adjustment may be necessary in clozapine-treated smokers.
对44名精神分裂症住院患者的血清氯氮平及其主要代谢物去甲基氯氮平浓度进行了测定，其中10名不吸烟者，34名吸烟者。在比较他们与氯氮平剂量和体重相关的血清药物水平时，我们发现吸烟者的氯氮平和去甲基氯氮平浓度比不吸烟组低约40%，这可能是由于吸烟对参与氯氮平代谢的细胞色素P450（CYP）1A2有诱导作用。我们得出结论，接受氯氮平治疗的吸烟者可能需要调整剂量。
